Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced Patients

Publisher Website
Google Scholar
Abstract
The main objective of the study was to evaluate patients' adherence to a fixed dose combination containing abacavir, zidovudine, and lamivudine (TZV) and to evaluate whether TZV might improve general satisfaction and quality of life (QOL) with anti-HIV treatment. Patients with viral load (VL) 95%, reaching 75% and 100% among the intravenous drug user population by ITT and PP analysis, respectively. General satisfaction was significantly higher at week 24 (90 +/- 14 vs. 53 +/- 26) in both ITT and PP populations (p<.0001). There were no statistically significant differences in QOL. Total cholesterol and triglycerides levels decreased significantly at week 24 compared to baseline (p<.05). Patients who switched to TZV showed an increase in general satisfaction and high levels of adherence.

This publication has 12 references indexed in Scilit: